Clinical Trial Update: AN0025 and Pembrolizumab Combination in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update announcing AN0025 in combination with pembrolizumab for advanced solid tumors; the study includes several indications and is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• AN0025
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Adlai Nortye Biopharma Co., Ltd. | Conditions: Triple-negative Breast Cancer, NSCLC, Squamous or Non-Squamous | Phase 1 | Status: ACTIVE_NOT_RECRUITING